After giving its contribution to the revision of the Ph. Eur. monograph on Cannabis flowers (07/2024:3028) and Cannabidiol (07/2024:3151) published in 2024, Linnea has been invited by the EDQM, under the auspices of the Swiss Pharmacopoeia, to participate in the development of the European Monograph for Cannabis extracts, which is currently being drafted in preparation for its publication in Pharmeuropa for public comment.
EDQM (European Directorate for the Quality of Medicines and HealthCare) is a division of the Council of Europe, responsible for ensuring the quality of medicines across Europe. It sets standards for pharmaceutical products and ingredients, including botanicals and produces the European Pharmacopoeia (Ph. Eur.), which provides legally binding quality standards.
As medical cannabis advances towards prime pharmaceutical criteria, Linnea is proud to lead the way by already applying these principles. We are honored to contribute to this vital work, reinforcing our role in advancing the development of the highest industry standards for cannabis-based products and shaping the future of safe, effective therapies for patients.
